107150 Federal Register / Vol. 89, No. 250 / Tuesday, December 31, 2024 / Notices 

(3) Develop, implement, and manage 

novel, innovative scientific and 

technical programs to democratize 

access to life-saving innovations and 

reduce disparities in health outcomes 

across the United States. (4) Propose 

agency-sponsored research programs to 

the ARPA–H Director, ensuring they 

align with strategic objectives. 

The Proactive Health Office 

The Proactive Health Office (PHO) is 

comprised of: 

1. Director 

2. Deputy Director 

3. Such other staff as necessary to 

support the PHO. 

PHO’s functions and responsibilities 

are as follows: (1) Improve personal 

health and wellness to reduce the 

likelihood that people will become 

patients. (2) Establish preventative 

programs that create new capabilities to 

identify and characterize disease risk, 

reduce comorbidities, and promote 

treatments and behaviors to address 

challenges to Americans’ health, 

whether those are viral, bacterial, 

physical, psychological, or caused by 

the natural aging process. (3) Develop, 

implement, and manage novel, 

innovative scientific and technical 

programs aimed at improving health 

outcomes. (4) Propose agency-sponsored 

research programs to the ARPA–H 

Director, ensuring they align with 

strategic objectives. 

The Project Accelerator Transition 

Innovation Office 

The Project Accelerator Transition 

Innovation Office (PATIO) is comprised 

of: 

1. Director 

2. Deputy Director 

3. Such other staff as necessary to 

support the PATIO. 

PATIO’s missions and responsibilities 

are as follows: (1) Increase the 

probability that solutions thrive 

independently after they transition from 

ARPA–H. (2) Provide a wide variety of 

services to Program Managers (PMs) and 

ARPA–H performers throughout the 

entire program lifecycle. (3) Provide a 

tailored, full-suite of entrepreneurial 

and tech-to-market services to ARPA–H 

program managers and performers, 

including access to C-suite level talent 

to advise on various topics: clinical, 

business, user adoption, manufacturing, 

landscape analysis, and regulatory 

matters. (4) Manage ARPA–H’s Small 

Business Innovation Research (SBIR). 

(5) Ensure capabilities are primarily 

designed for user experience. Provide 

Minimum Viable Product (MVP) and 

market-testing experimentation to 

uncover insights into customer 

desirability, access, and trust. (6) 

Maintain ARPANET–H, including the 

Investor Catalyst and Customer 

Experience Hub and Spoke Network to 

create a Nationwide Health Innovation 

Network for ARPA–H to help 

performers bring their ideas to market. 

(7) Develop a unique portfolio to 

address challenging problems related to 

health for fostering revolutionary 

advances and paradigm shifts. (8) 

Propose agency-sponsored research 

programs to the ARPA–H Director, 

ensuring they align with strategic 

objectives. 

The Office of Operations 

The Office of Operations (OO) is 

comprised of: 

1. Director 

2. Deputy Director 

3. Such other staff as necessary to 

support the OO. 

OO’s functions and responsibilities 

are as follows: (1) Advise the ARPA–H 

Director and staff on the planning, 

development, and implementation of 

agency Business Operation services. (2) 

Lead all aspects of internal business 

operations, including ongoing 

management of the agency’s financial 

and budget activities, human capital, 

contracting and acquisitions, and other 

administrative and operational activities 

including but not limited to travel and 

training. (3) Oversee the creation of 

relevant business operations Standard 

Operating Procedures (SOPs), develops 

tracking and reporting processes and 

tools, provides high-level input to 

inform legal and financial risk, and 

develops systems that support 

administrative processes within the 

agency. (4) Oversee the Agency’s 

security related procedures and 

programs including research security 

risk and supply chain risk management. 

(5) Manage ARPA–H’s regional footprint 

and associated infrastructure across hub 

locations, including facilities and space 

management. (6) Oversee management 

of ARPA–H’s official records 

management in collaboration with 

Office of Information Technology and 

Data Innovation. 

The Office of Information Technology 

and Data Innovation 

The Office of Information Technology 

and Data Innovation (ITDI) is comprised 

of: 

1. The Chief Technology Officer 

2. The Chief Information Officer 

3. The Chief Information and Security 

Officer 

4. The Chief Data Officer 

5. Such other staff as necessary to 

support the ITDI Office. 

ITDI’s functions and responsibilities 

are as follows: (1) Advise the ARPA–H 

Director, staff, and programs on every 

aspect of Information Technology (IT) 

and Data modernization, governance, 

and allocation of relevant technology 

and communication resources to drive 

the agency’s mission. (2) Support the 

research, development, launch, and 

maintenance of tools to support data 

governance, innovation, and analytics 

across the agency, including data needs 

for program development. (3) Lead 

development of agency-wide IT, AI/ML, 

Technology Infrastructure, Cloud 

Computing, Networking, End User 

Computing, Cybersecurity, Technology 

Compliance, Telecommunications, and 

Responsible use of Technology Policy. 

(4) Develop and implement enterprise 

solutions to enable lean and agile 

business operations and collaboration. 

(5) Leads agency efforts to ensure user 

and data privacy and security 

management across all platforms and 

services. (6) Liaise with HHS and across 

the U.S. government to ensure 

compliance and consistency with U.S. 

government policy impacting IT tools 

and services, as well as data storage and 

analysis. (7) Conduct life cycle 

investment planning and monitoring as 

needed to support the areas listed 

above. 

Xavier Becerra, 

Secretary, Department of Health and Human 

Services. 

[FR Doc. 2024–31364 Filed 12–26–24; 11:15 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases; 


khammond on DSK9W7S144PROD with NOTICES
Federal Register / Vol. 89, No. 250 / Tuesday, December 31, 2024 / Notices 107151 

Initial Review Group Diabetes, 

Endocrinology and Metabolic Diseases B 

Study Section Diabetes, Endocrinology and 

Metabolic Diseases B Study Section (DDK–B). 

Date: March 5–7, 2025. 

Time: 10:00 a.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 6707 

Democracy Boulevard, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Charlene J. Repique, Ph.D., 

Scientific Review Officer, National Institute 

of Diabetes and Digestive and Kidney 

Diseases, National Institutes of Health, 6707 

Democracy Boulevard, Rm 7347, Bethesda, 

MD 20892–5452, (301) 451–3638, 

charlene.repique@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: December 20, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–31180 Filed 12–30–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–10: 

NCI Clinical and Translational Cancer 

Research. 

Date: March 4, 2025. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Cancer Institute at 

Shady Grove, 9609 Medical Center Drive, 

Room 7W240, Rockville, Maryland 20850. 

Meeting Format: Virtual Meeting. 

Contact Person: Hasan Siddiqui, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W240, Rockville, 

Maryland 20850, 240–276–5122, 

hasan.siddiqui@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Integrating 

Biospecimen Science Approaches into 

Clinical Assay Development. 

Date: March 26, 2025. 

Time: 1:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W624, Rockville, Maryland 20850. 

Meeting Format: Virtual Meeting. 

Contact Person: Tushar Deb, Ph.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W624, Rockville, Maryland 20850, 

240–276–6132, tushar.deb@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: December 20, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–31171 Filed 12–30–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group; Digestive Diseases and 

Nutrition C Study Section DDK–C Mentored 

Career Development Applications in 

Digestive Diseases and Nutrition. 

Date: March 19–20, 2025. 

Time: 5:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute of Diabetes and Digestive 

and Kidney Diseases, Democracy II, Suite 

7000A, 6707 Democracy Boulevard, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Peter J. Kozel, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

National Institute of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7009, Bethesda, MD 20892– 

5452, (301) 594–4721, kozelp@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: December 20, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–31183 Filed 12–30–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Beeson 

applications review. 

Date: February 25, 2025. 

Time: 9:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institute on Aging, 5601 

Fishers Lane, Suite 8B, Rockville, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Gianina Ramona 

Dumitrescu, Ph.D., MPH, Scientific Review 

Officer, National Institute on Aging, National 


khammond on DSK9W7S144PROD with NOTICES